2022 marks the 10th anniversary of our International Linked Clinical Trials (iLCT) programme. Since it was launched over 3,700 people have taken part in iLCT trials; 17 trials are ongoing, 11 trials have completed and 40 drugs are actively being pursued within the programme. There are only three disease-modifying phase 3 trials for Parkinson’s currently underway or imminent, and two of these have been directed through the iLCT process.

(Please note: these statistics are correct at the time of posting)

Each month throughout this anniversary year, we will be bring you the latest update from the programme.

Here, Dr. Simon Stott, Deputy Director of Research, explains the criteria that potential drugs and compounds must meet before being advanced through the iLCT process and into clinical trials for the Parkinson’s community.

The latest updates from the iLCT programme

The liraglutide trial results

Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the iLCT liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living and non-motor symptoms in people with Parkinson’s.

Read more here
The Anle138b trial results

Anle138b is a new drug that was prioritised by our International Linked Clinical Trials (iLCT) committee in 2019 as a potential drug to target the build-up of alpha synuclein, a protein that clumps together in Parkinson’s and is involved in the progression of the disease.

Read more here
The International Linked Clinical Trials (iLCT) programme

Cure Parkinson’s iLCT programme seeks to significantly reduce the time taken to bring much needed and potentially curative treatments into the clinic for the Parkinson’s community; there are iLCT trials that are actively recruiting participants now.

Find out more about taking part

CEO Will Cook and Director of Research Dr. Richard Wyse discuss the founding and development of one of the most successful and pioneering drug-repurposing and repositioning programmes in the world.